BRPI0906045A2 - "composição farmacêutica para administração nasal" - Google Patents

"composição farmacêutica para administração nasal"

Info

Publication number
BRPI0906045A2
BRPI0906045A2 BRPI0906045-6A BRPI0906045A BRPI0906045A2 BR PI0906045 A2 BRPI0906045 A2 BR PI0906045A2 BR PI0906045 A BRPI0906045 A BR PI0906045A BR PI0906045 A2 BRPI0906045 A2 BR PI0906045A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
nasal administration
nasal
administration
pharmaceutical
Prior art date
Application number
BRPI0906045-6A
Other languages
English (en)
Inventor
Mariko Morishita
Kozo Takayama
Nobuo Ida
Reiji Nishio
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of BRPI0906045A2 publication Critical patent/BRPI0906045A2/pt
Publication of BRPI0906045B1 publication Critical patent/BRPI0906045B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Insects & Arthropods (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0906045-6A 2008-02-28 2009-02-27 Composição farmacêutica para administração nasal BRPI0906045B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008-048300 2008-02-28
JP2008048300 2008-02-28
PCT/JP2009/053648 WO2009107766A1 (ja) 2008-02-28 2009-02-27 経鼻投与用医薬組成物

Publications (2)

Publication Number Publication Date
BRPI0906045A2 true BRPI0906045A2 (pt) 2015-07-07
BRPI0906045B1 BRPI0906045B1 (pt) 2022-01-25

Family

ID=41016151

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906045-6A BRPI0906045B1 (pt) 2008-02-28 2009-02-27 Composição farmacêutica para administração nasal

Country Status (13)

Country Link
US (1) US8895503B2 (pt)
EP (1) EP2253326B1 (pt)
JP (2) JP4711013B2 (pt)
KR (1) KR101585046B1 (pt)
CN (1) CN101959532B (pt)
AU (1) AU2009218060B2 (pt)
BR (1) BRPI0906045B1 (pt)
CA (1) CA2716565C (pt)
ES (1) ES2671024T3 (pt)
MX (1) MX2010009148A (pt)
PL (1) PL2253326T3 (pt)
RU (1) RU2470666C2 (pt)
WO (1) WO2009107766A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010134537A1 (ja) * 2009-05-20 2010-11-25 東レ株式会社 細胞膜透過性ペプチド
JP2014502953A (ja) * 2010-08-16 2014-02-06 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 細胞透過性治療薬の鼻腔内送達
EP3776557B1 (en) * 2018-04-13 2025-01-29 The Hong Kong Polytechnic University Data storage using peptides
WO2019222400A2 (en) * 2018-05-15 2019-11-21 Dnalite Therapeutics, Inc. Mucus-penetrating peptides, delivery vehicles and methods of therapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
JPS6068176A (ja) * 1983-09-26 1985-04-18 Kobe Steel Ltd 厚板Ｃｒ―Ｍｏ―Ｖ系耐熱鋼の突合わせ溶接方法
US4789660A (en) * 1987-09-10 1988-12-06 American Home Products Corporation Insulin administration using methyl and propyl paraben
JPH0242027A (ja) 1988-08-02 1990-02-13 Minofuaagen Seiyaku Honpo:Goushi 経粘膜吸収促進剤及びこれを用いた経鼻投与剤
EP0903408A3 (en) 1992-08-21 2005-11-02 Biogen, Inc. Tat-derived transport polypeptide
AU7977294A (en) * 1993-10-07 1995-05-01 Odontex, Inc. Absorption enhancers for topical pharmaceutical formulations
HUP9900017A3 (en) * 1995-09-21 2001-08-28 Andaris Ltd Ruddington Transcytosis vehicles and enhancers for drug delivery
JP3770666B2 (ja) 1996-09-20 2006-04-26 株式会社ティ・ティ・エス技術研究所 経粘膜吸収製剤用組成物
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
AU762145C (en) * 1998-08-26 2005-03-17 Teijin Limited Powdery pernasal compositions
ATE419273T1 (de) 1998-11-13 2009-01-15 Cyclacel Ltd Translokationsvektoren abgeleitet von der antennapedia homeodomain helix 3
AU2002327531A1 (en) * 2001-08-22 2003-03-10 Myriad Genetics, Inc Therapeutic compositions and methods for treating viral infection
US20040254146A1 (en) * 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
KR20050049525A (ko) * 2002-10-11 2005-05-25 가부시키가이샤산와카가쿠켄큐쇼 Ｇｌｐ-1 유도체 및 그의 경점막 흡수형 제제
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US20040147027A1 (en) * 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
US7329638B2 (en) * 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
EP1790351A4 (en) * 2004-09-15 2009-11-04 Otsuka Pharma Co Ltd PERMUCOSAL COMPOSITION AND METHOD FOR IMPROVING PERMUCOSAL ABSORPTION
US7442682B2 (en) * 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
JP5103748B2 (ja) * 2005-02-16 2012-12-19 東レ株式会社 医薬組成物
KR100729830B1 (ko) * 2005-03-24 2007-06-19 바이오스펙트럼 주식회사 페너트라틴을 이용하여 단백질의 세포투과를 증진시키는대장균용발현벡터
WO2006112738A1 (en) * 2005-04-19 2006-10-26 Auckland Uniservices Limited Novel peptides and methods for the treatment of inflammatory disorders
CA2616778A1 (en) * 2005-07-27 2007-02-01 Nastech Pharmaceutical Company Inc. Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents
ATE478676T1 (de) * 2005-11-04 2010-09-15 Forhumantech Co Ltd Verfahren zur abgabe von fusionspolypeptid in eine zelle
AU2006332193B2 (en) * 2005-12-30 2012-06-28 Evonik Operations Gmbh Lactoferrin peptides useful as cell-penetrating peptides
JP2009539856A (ja) * 2006-06-08 2009-11-19 シーペックス ファーマシューティカルズ インコーポレイテッド インシュリン組成物
JP5076374B2 (ja) * 2006-06-28 2012-11-21 東レ株式会社 医薬組成物
WO2008022046A2 (en) * 2006-08-18 2008-02-21 Nastech Pharmaceutical Company Inc. Dicer substrate rna peptide conjugates and methods for rna therapeutics

Also Published As

Publication number Publication date
CN101959532B (zh) 2013-02-27
JP2011084581A (ja) 2011-04-28
AU2009218060A1 (en) 2009-09-03
ES2671024T3 (es) 2018-06-04
RU2010139769A (ru) 2012-04-10
EP2253326B1 (en) 2018-04-04
US20110020280A1 (en) 2011-01-27
JP4711013B2 (ja) 2011-06-29
PL2253326T3 (pl) 2018-09-28
EP2253326A1 (en) 2010-11-24
CA2716565C (en) 2017-09-12
BRPI0906045B1 (pt) 2022-01-25
KR101585046B1 (ko) 2016-01-13
RU2470666C2 (ru) 2012-12-27
AU2009218060B2 (en) 2014-08-28
US8895503B2 (en) 2014-11-25
MX2010009148A (es) 2010-12-06
CN101959532A (zh) 2011-01-26
EP2253326A4 (en) 2013-01-09
JP5212492B2 (ja) 2013-06-19
JPWO2009107766A1 (ja) 2011-07-07
KR20100135730A (ko) 2010-12-27
WO2009107766A1 (ja) 2009-09-03
CA2716565A1 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
BRPI0808293A2 (pt) "composições para administração nasal"
LTPA2018014I1 (lt) Farmacinė kompozicija 514
BRPI0810928A2 (pt) "composição farmacêutica"
LTC2140867I2 (lt) Farmacinė kompozicija
PL2136865T3 (pl) Podawanie donosowe
EP2381773A4 (en) COMPOSITIONS FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS
BRPI0913379A2 (pt) formulações farmacêuticas sólidas compreendendo bibw 2992
BRPI0916877A2 (pt) composição farmacêutica e administração da mesma
BRPI0721651A2 (pt) Composição farmacêutica
BRPI0820381A2 (pt) Formulações farmacêuticas
BRPI1008598A2 (pt) composição farmacêutica para inalação
PT2066179T (pt) Formulações para administração tópica local contendo indoxacarb
EP2152195A4 (en) PEPTIDATE MEDICINAL FOR ORAL LEVY
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
DK2120884T3 (da) Farmaceutisk sammensætning
BRPI0809661A2 (pt) Composição farmacêutica estabilizada contendo pregabalina
DE602007002909D1 (de) Geschoss zur verabreichung eines medikaments
EP2643009A4 (en) COMPOSITION FOR THE RELEASE OF BIODEGRADABLE ACTIVE SUBSTANCES
BRPI1007484A2 (pt) composição farmacêutica para administração oral
PT2209464E (pt) Composição farmacêutica antimalárica
EP2193795A4 (en) AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING LATANOPROST
EP2062579A4 (en) SOLID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING OPTICALLY STABLE RAMOSETRON
BRPI0918539A2 (pt) preparação farmacêutica sólida para administração oral
BRPI1005932A2 (pt) composto, composição farmacêutica para inalação e inalador
DK2271321T3 (da) Farmaceutisk sammensætning 271

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/02/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2763 DE 19-12-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.